drugset / Trial / NCT03776032

A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy

NCT03776032

Phase 3 Completed 320 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study was to compare the effectiveness of darbopoetin alfa to placebo in the treatment of anemia in adults with lung cancer receiving multicycle platinum-containing chemotherapy, by assessing the percentage of participants who received red blood cell (RBC) transfusions during weeks 5-12 inclusive.

Timeline

Start
1999-09-14
Primary completion
2000-11-08
Completion
2002-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 2.25 ug/kg Subcutaneous
Subject Darbepoetin alfa Protein / enzyme biologic 4.5 ug/kg Subcutaneous

Indications